NasdaqGM:HROWPharmaceuticals
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story
Harrow received FDA clearance of its Investigational New Drug application for TRIESENCE, allowing a Phase 3 clinical trial to proceed.
This regulatory decision marks a key clinical milestone for the company’s ophthalmic drug pipeline.
The TRIESENCE Phase 3 program adds a new pillar to Harrow's story beyond previously discussed earnings and financial guidance.
Harrow, trading on NasdaqGM:HROW, now has a fresh clinical catalyst in play alongside its existing commercial portfolio. The stock...